LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Perimyocarditis in Adolescents After Pfizer-BioNTech COVID-19 Vaccine.

    Tano, Eric / San Martin, Stephanie / Girgis, Stephen / Martinez-Fernandez, Yadira / Sanchez Vegas, Carolina

    Journal of the Pediatric Infectious Diseases Society

    2021  Volume 10, Issue 10, Page(s) 962–966

    Abstract: On May 10, 2021, the Emergency Use Authorization of the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2 ... coronavirus-covid-19-update-fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use). We describe ... Hospital with perimyocarditis within 4 days of receiving a dose of BNT162b2 vaccine. ...

    Abstract On May 10, 2021, the Emergency Use Authorization of the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) was expanded to include adolescents (May 10, 2021. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use). We describe clinical characteristics of 8 adolescents who presented over the course of 36 days to Nicklaus Children's Hospital with perimyocarditis within 4 days of receiving a dose of BNT162b2 vaccine.
    MeSH term(s) Adolescent ; COVID-19 ; COVID-19 Vaccines ; Child ; Humans ; SARS-CoV-2
    Chemical Substances COVID-19 Vaccines ; BNT162 vaccine (N38TVC63NU)
    Language English
    Publishing date 2021-07-28
    Publishing country England
    Document type Journal Article
    ZDB-ID 2668791-4
    ISSN 2048-7207 ; 2048-7193
    ISSN (online) 2048-7207
    ISSN 2048-7193
    DOI 10.1093/jpids/piab060
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Acute Perimyocarditis in an Adolescent Japanese Male after a Booster Dose of the BNT162b2 COVID-19 Vaccine.

    Morita, Yusuke / Matsubara, Daisuke / Seki, Mitsuru / Tamura, Daisuke / Tajima, Toshihiro

    The Tohoku journal of experimental medicine

    2022  Volume 258, Issue 3, Page(s) 177–182

    Abstract: ... who had completed a two-dose primary series of the BNT162b2 (Pfizer-BioNTech) vaccine six months prior ... Perimyocarditis is a rare and serious cardiac complication following COVID-19 vaccination. Young ... some reports have focused on the risk of perimyocarditis after a booster dose. However, no currently available ...

    Abstract Perimyocarditis is a rare and serious cardiac complication following COVID-19 vaccination. Young males are most at risk after the second dose. With the introduction of the booster (third) dose, some reports have focused on the risk of perimyocarditis after a booster dose. However, no currently available report in Japan has comprehensively described this phenomenon. A healthy 14-year-old Japanese male, who had completed a two-dose primary series of the BNT162b2 (Pfizer-BioNTech) vaccine six months prior, developed fever and chest pain within 24 hours after a homologous booster dose. He was transferred to our institute because of worsening chest pain. A multiplex PCR test showed no evidence of active viral infections, including SARS-CoV-2. Electrocardiography revealed ST-segment elevation in almost all leads, suggesting pericarditis. Echocardiography showed normal systolic function. Laboratory data demonstrated C-reactive protein levels of 8.8 mg/dL and elevated cardiac damage markers (troponin T, 1.9 ng/mL; creatine phosphokinase, 1527 U/L; MB isoenzyme, 120 U/L), suggesting myocarditis. He was diagnosed with perimyocarditis associated with the booster dose, which was confirmed by cardiac magnetic resonance imaging four days after initial symptoms. Chest pain improved spontaneously along with a resolution of electrocardiographic findings and laboratory data within several days. He was discharged eight days after admission. Perimyocarditis is less frequent after a booster dose than after primary doses. In this case, the patient with booster-dose-associated perimyocarditis showed favorable clinical course without severe sequelae. The patient's clinical course was consistent with findings on previous large-scale reports on primary-dose-associated perimyocarditis and case series on booster-dose-associated perimyocarditis.
    MeSH term(s) Adolescent ; Humans ; Male ; BNT162 Vaccine/adverse effects ; C-Reactive Protein/metabolism ; Chest Pain ; COVID-19/complications ; COVID-19 Vaccines/adverse effects ; Creatine Kinase ; Isoenzymes ; Japan ; Myocarditis/diagnosis ; Myocarditis/etiology ; SARS-CoV-2 ; Troponin T
    Chemical Substances BNT162 Vaccine ; C-Reactive Protein (9007-41-4) ; COVID-19 Vaccines ; Creatine Kinase (EC 2.7.3.2) ; Isoenzymes ; Troponin T
    Language English
    Publishing date 2022-08-25
    Publishing country Japan
    Document type Case Reports
    ZDB-ID 123477-8
    ISSN 1349-3329 ; 0040-8727
    ISSN (online) 1349-3329
    ISSN 0040-8727
    DOI 10.1620/tjem.2022.J068
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.155: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top